Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Macy's Inc (M) Price & Performance

Biogen IncTrade
Macy's IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Macy's Inc — how do they compare? Biogen Inc trades at $203.9 (market cap $30.60B), while Macy's Inc trades at $24.53 (market cap $6.68B). The key difference: Biogen Inc is far larger — about 4.6× Macy's Inc's market cap, and Macy's Inc pays a 3.02% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

BIIBM
Market Cap
$30.60B$6.68B
Sector
HealthConsumer Cyclical
52-Week High
$216.63$26.21
52-Week Low
$128.93$12.73
Enterprise Value
$37.67B$10.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.

The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.

Macy's Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M